EUGIA PHARMA
GenericsEUGIA PHARMA is a generic drug manufacturer focused on Oncology, Infectious Disease, Dermatology.
EUGIA PHARMA's Key Drugs
EUGIA PHARMA's core commercial portfolio centers on CISATRACURIUM BESYLATE PRESERVATIVE FREE, spanning Oncology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
EUGIA PHARMA's Recent FDA Approvals
EUGIA PHARMA secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
EUGIA PHARMA's Therapeutic Areas
EUGIA PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EUGIA PHARMA's Top Competitors
EUGIA PHARMA's closest competitors by therapeutic-area and drug-target overlap include Baxter, Pfizer, and FOUGERA PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EUGIA PHARMA Pipeline Snapshot
Active clinical trials for EUGIA PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CISATRACURIUM BESYLATE PRESERVATIVE FREE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1994-04-26
- Latest
- 2026-05-27
- Applications
- 158